How does glutathione depletion play a role in the development of cancer? 

Glutathione depletion plays a crucial role in the development of cancer. Elevated levels of glutathione (GSH) in tumor cells are associated with tumor progression and increased resistance to chemotherapeutic drugs . GSH acts as an intracellular antioxidant, protecting cells from damage caused by reactive oxygen and nitrogen species, lipid peroxides, and xenobiotics . However, in cancer cells, high levels of GSH are necessary to scavenge excessive reactive oxygen species (ROS) and detoxify xenobiotics, making it a potential target for cancer therapy . Depleting intracellular GSH makes cancer cells more susceptible to oxidative stress and chemotherapeutic agents, improving the therapeutic efficacy of ROS-based therapy, ferroptosis, and chemotherapy . Various strategies for GSH depletion have been explored, including the use of GSH-consuming agents, nanomedicine, and the convergence of GSH-scavenging agents with therapeutic drugs . These approaches have shown promising results in preclinical studies, enhancing the outcomes of various therapeutic regimens and providing potential guidance for designing intelligent drug delivery systems .

Self-immolative nanosensitizer for glutathione depletion- assisted sonodynamic therapy

The provided paper does not directly discuss how glutathione depletion plays a role in the development of cancer.

Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy.

Glutathione depletion in cancer cells makes them more susceptible to oxidative stress and chemotherapy, improving therapeutic efficacy.

(Salen)osmium(VI) nitrides catalyzed glutathione depletion in chemotherapy

Glutathione depletion can be a strategy for designing non-platinum anticancer drugs, as it induces apoptosis and autophagy in cancer cells.